Gefitinib (`Iressa`, ZD1839) is active against brain metastases in a 77 year old patient.
Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)
Posted on: 03/10/2005
Gefitinib ('Iressa', ZD1839) is active against brain metastases in a 77 year old patient.
J Neurooncol. 2005 Feb;71(3):277-80.
Roggero E, Giancarla B, Antonella P, Augusto P.
Oncologia Lago Maggiore, Humaine Clinica S. Chiara, Via Franscini 4, 6600, Locarno, Ticino, Switzerland, email@example.com.
This report highlights the case of a symptomatic 77-year-old non-smoking female patient who was diagnosed with advanced non-small-cell lung cancer (NSCLC), metastatic to the liver and contralateral lung. After tumor progression in the liver and lung following polychemotherapy, multiple diffuse brain and cerebellar metastases were apparent. Oral treatment with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa') 250 mg/day resulted in progressive and durable symptom relief, and improvements in quality of life and performance status. Reductions in the size of the primary pulmonary tumor and brain, cerebellar, and liver metastases were observed. Furthermore, gefitinib was well tolerated with an absence of adverse events. These results provide evidence that oral gefitinib is active in patients with advanced NSCLC and central nervous system metastases.
PMID: 15735917 [PubMed - in process]
Click HERE to return to brain tumor news headlines